Bluefin Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bluefin Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,237	Closed	-$122K	–	973
2021 Q4	$122K	Sell	15,237 -27,000	-64%	-$244K	0.01%	598
2021 Q3	$411K	Sell	42,237 -11,000	-21%	-$103K	0.04%	311
2021 Q2	$527K	Buy	53,237 +26,600	+100%	+$282K	0.03%	264
2021 Q1	$307K	Buy	+26,637	New	+$305K	0.01%	392
2017 Q1	–	Sell	-10,162	Closed	-$368K	–	628
2016 Q4	$368K	Buy	+10,162	New	+$406K	0.02%	256
2016 Q1	–	Sell	-22,286	Closed	-$1.46M	–	712
2015 Q4	$1.46M	Buy	22,286 +1,381	+7%	+$85.3K	0.12%	191
2015 Q3	$1.18M	Sell	20,905 -56,383	-73%	-$3.66M	0.07%	172
2015 Q2	$4.57M	Buy	+77,288	New	+$4.77M	0.28%	77
2015 Q1	–	Sell	-46,012	Closed	-$2.65M	–	622
2014 Q4	$2.65M	Buy	46,012 +18,412	+67%	+$1.03M	0.16%	146
2014 Q3	$1.48M	Buy	+27,600	New	+$1.46M	0.08%	239

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Bluefin Capital Management's TEVA Position: Q1 2022 in Review

Bluefin Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 15,237 shares — an estimated $122K sold.

Bluefin Capital Management first reported a position in TEVA in Q3 2014 and held it in 10 quarters. The position peaked at $4.57M in Q2 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

Bluefin Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Bluefin Capital Management sold 15,237 Teva Pharmaceuticals shares in Q1 2022, an estimated $122K.
Bluefin Capital Management first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Bluefin Capital Management's Teva Pharmaceuticals position peaked at $4.57M in Q2 2015.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.